PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan .

MADRID, June 26, 2018 / PRNewswire/ .

• PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000 from Chugai 
• PharmaMar progresses in the clinical development of Zepsyre® in Japanwhile its ATLANTIS global registration trial in small-cell lung cancer continues 
• ATLANTIS trial has successfully passed two safety analyses by the IDMC after inclusion of 150 and 500 patients, respectively .  ...